ArticlePloS one2020
A screening of the MMV Pathogen Box® reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Auranofin and iodoquinol as promising repurposing drugs against filamentous fungi: antifungal activity and cellular alterations.Microbiology spectrum · 2026Article
- In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin.International journal of molecular sciences · 2025Review
- Monolaurin inhibits antibiotic-resistant Staphylococcus aureus in patients with atopic dermatitis.Scientific reports · 2025Article
- Multidrug-resistant keratinolytic dermatophytes and non-dermatophytes causing onychomycosis in outpatients.Future microbiology · 2025Article
- Novel drug candidates targetingFrontiers in pharmacology · 2025Article
- Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes.PLoS neglected tropical diseases · 2024Article
- In vitro antifungal activity of MMV Pathogen Box® compounds alone or in combination with antifungal drugs against mucormycosis agents.Current research in microbial sciences · 2024Article
- Screening of MMV pandemic response and pathogen box compounds against pan-drug-resistantNew microbes and new infections · 2023Article
- Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey.PLoS neglected tropical diseases · 2023Article
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- Mebendazole InhibitsJournal of fungi (Basel, Switzerland) · 2023Article
- Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.PloS one · 2023Article
- Article
- In vitro activity of Schinus terebinthifolius extract and fractions against Sporothrix brasiliensis.Memorias do Instituto Oswaldo Cruz · 2022Article
- New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.Memorias do Instituto Oswaldo Cruz · 2022Article
- Identification of Promising Antifungal Drugs againstJournal of fungi (Basel, Switzerland) · 2021Article
- Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi.Memorias do Instituto Oswaldo Cruz · 2021Article
- Gut Microbial Alterations in Diarrheal Baer's Pochards (Frontiers in veterinary science · 2021Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by traumatic implantation of many species of black fungi. Due to the refractoriness of some cases and common recurrence of CBM, a more effective and less time-consuming treatment is mandatory. The aim of this study was to identify compounds with in vitro antifungal activity in the Pathogen Box® compound collection against different CBM agents. Synergism of these compounds with drugs currently used to treat CBM was also assessed. An initial screening of the drugs present in this collection at 1 μM was performed with a Fonsecaea pedrosoi clinical strain according to the EUCAST protocol. The compounds with activity against this fungus were also tested against other seven etiologic agents of CBM (Cladophialophora carrionii, Phialophora verrucosa, Exophiala jeanselmei, Exophiala dermatitidis, Fonsecaea monophora, Fonsecaea nubica, and Rhinocladiella similis) at concentrations ranging from 0.039 to 10 μM. The analysis of potential synergism of these compounds with itraconazole and terbinafine was performed by the checkerboard method. Eight compounds inhibited more than 60% of the F. pedrosoi growth: difenoconazole, bitertanol, iodoquinol, azoxystrobin, MMV688179, MMV021013, trifloxystrobin, and auranofin. Iodoquinol produced the lowest MIC values (1.25-2.5 μM) and MMV688179 showed MICs that were higher than all compounds tested (5 - >10 μM). When auranofin and itraconazole were tested in combination, a synergistic interaction (FICI = 0.37) was observed against the C. carrionii isolate. Toxicity analysis revealed that MMV021013 showed high selectivity indices (SI ≥ 10) against the fungi tested. In summary, auranofin, iodoquinol, and MMV021013 were identified as promising compounds to be tested in CBM models of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.